Compare Iron Mountain Inc (IRM) vs TG Therapeutics Inc (TGTX) Price & Performance

Iron Mountain (IRM) trades at $124.38, up 0.45% for the day, with a bullish technical signal and strong recent earnings beats. The stock has rallied 30.2% over three months, supported by data center growth and recurring storage revenue. However, the company faces high debt levels, with a debt-to-asset ratio of 74.39% in 2024, and a P/E ratio of 134.59 suggests elevated valuation. Analyst consensus is bullish with a $138.67 price target, though the RSI_6 at 84.86 indicates potential overbought conditions near-term.

Outlook remains positive due to consistent earnings outperformance and data center expansion, but risks include significant leverage and declining paper storage demand. The stock offers a dividend yield with a recent $0.86 payment, yet investors should weigh high valuation multiples against growth prospects in a competitive information services sector.

TG Therapeutics (TGTX) trades at $53.96, down 1.6% on the day, with mixed technical signals showing a neutral overall trend. The company demonstrates strong profitability with 65.95% net income margin and 112.6% ROE, though recent earnings have missed expectations in two of the last three quarters. Positive clinical developments for Briumvi in multiple sclerosis and schizophrenia trials provide growth catalysts, while a shareholder investigation presents near-term uncertainty.

The outlook remains cautiously optimistic with 84.6% analyst buy ratings but a consensus price target of $48.50 below current levels. Key opportunities include Briumvi's expanding indications and strong revenue growth, while risks involve clinical trial outcomes, the ongoing legal investigation, and premium valuations with P/E of 19.2 and P/S of 12.6.